BUSINESS INSIGHTS, PHARMACY MARKET
Shields Health Solutions | January 12, 2023
Shields Health Solutions (ShieldsRx), one of the leading specialty pharmacy accelerators, informed that the company has now collaborated with more than 850 hospitals at over 75 health systems after adding four more health systems.
ShieldsRx health system partners are well-positioned to improve therapy management and care coordination for critical patients, improving outcomes through high-quality care. Its health systems serve 1 million patients in 44 states.
Matt Conway, Chief Commercial Growth Officer of ShieldsRx stated, "As the foremost expert in health system specialty pharmacy, Shields has proven successful in partnering with health system leaders to develop integrated programs that deliver superior experiences and outcomes for complex patients." He further stated, "Not only do these programs deliver measurable clinical results but integrating specialty pharmacy within the health system also creates the net operating income health systems need to succeed. These proven clinical and financial results are why so many leading health systems trust Shields to elevate access, outcomes and growth within specialty pharmacy."
(Source- PRNewswire)
ShieldsRx's expansion with new health system partnerships includes
MyMichigan Health: Midland-based MyMichigan Health serves 25 counties. Its urgent care, home health, virtual care, and medical offices offer a broad spectrum of care in over 30 specialties and subspecialties.
Nemours Children's Health: Nemours Children's Health, the nation's most extensive multistate pediatric health system, has two free-standing children's hospitals and over 70 general and specialized care practices.
Solution Health: Phoenix Children's Care Network, Arizona's leading children's hospital, offers over 1,175 pediatric primary care professionals and specialists in over 75 subspecialties.
Traditional specialty pharmacy patients had to tackle administrative difficulties like prior authorization and expensive medical bills alone. Shields' expansion facilitated value-based reimbursement.
About Shields Health Solutions
Shields Health Solutions is a leading specialized pharmacy accelerator. Its Performance Platform is designed to improve payer and drug access for specialty pharmacies, improve health outcomes for complex patients, and promote growth across the entire health system. The company has access to over 80% of limited distribution medications (LDDs) and major health insurance payers in the U.S. along with a clinical strategy that lowers the total cost of treatment by 13%. ShieldsRx has collaborated with more than 70 health systems to deliver measurable clinical and financial benefits.
Read More
BUSINESS INSIGHTS, PHARMA TECH
Innate Pharma | January 17, 2023
On January 16, 2023, Innate Pharma SA announced the publication of preclinical findings demonstrating the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123 in the scientific journal Nature Biotechnology. Innate and Sanofi conducted the experiments, which were published in Nature Biotechnology on January 12, 2023.
This study demonstrates that CD64 expression on AML blasts imparts resistance to anti-CD123 antibody-dependent cell cytotoxicity (ADCC) and that redirecting NK cells against cancer targets by binding to CD16a and NKp46 circumvents this resistance. Moreover, through their binding to NKp46, CD123-NKCE primarily target NK cells and have substantial antitumor activity against primary AML blasts; they stimulate NK cell activation and cytokine secretion exclusively in AML cells' presence.
In vivo, its antitumor activity observed in a mouse tumor model surpasses that of the anti-CD123 antibody used as the comparator. Furthermore, in vitro in human peripheral blood mononuclear cells and in vivo in nonhuman primates, the efficacy of CD123-NKCE was associated with the induction of low pro-inflammatory cytokine release and the absence of toxicity.
These results support CD123-NKCE clinical development. IPH6101/SAR'579 (SAR443579), the first NKp46/CD16-based CD123-targeted ANKETTM NK cell engager, is currently being evaluated in a Phase 1/2 clinical trial by Sanofi in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), or high-risk myelodysplastic syndrome (HR-MDS).
About Innate Pharma
Headquartered in Marseille (France), Innate Pharma SA is a global, clinical-stage oncology-focused biotech firm dedicated to enhancing patient treatment and clinical outcomes using therapeutic antibodies that employ the immune system to combat cancer. Its extensive antibody pipeline has numerous potentially first-in-class clinical and preclinical candidates for cancers with a high unmet medical need. In addition, Innate has been a pioneer in the study of natural killer cell (NK cell) biology and developed its expertise in tumor antigens, tumor microenvironment, and antibody engineering. This innovative strategy has resulted in a varied proprietary portfolio and substantial alliances with biopharmaceutical industry leaders, including Sanofi, Bristol-Myers Squibb, Novo Nordisk A/S, and a multi-product collaboration with AstraZeneca.
Read More
PHARMACY MARKET, PHARMA TECH
Capsida Biotherapeutics | February 27, 2023
Capsida Biotherapeutics Inc., a fully integrated next-generation gene therapy platform company, and AbbVie, a pharmaceutical company dedicated to discovering and providing innovative medicines to address serious health issues, have recently announced an expanded strategic collaboration.
The collaboration aims to develop genetic medicines for eye diseases with high unmet needs. Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability will be combined with AbbVie's extensive capabilities to identify and advance three programs. This expanded collaboration builds on the neurodegenerative disease partnership established in 2021.
As per the agreement's terms, Capsida will receive $70 million, comprising upfront payments and possible equity investment. Capsida could receive up to $595 million in option fees and research and development milestones for the three programs, with the potential for further commercial milestones. Additionally, Capsida will be eligible to receive mid-to-high single-digit royalty payments on future product sales.
Capsida will be responsible for leading capsid discovery efforts for all programs, utilizing its high throughput AAV engineering platform, and will also be responsible for process development and early clinical manufacturing. AbbVie, on the other hand, will lead innovative therapeutic cargo approaches and be responsible for commercialization and development.
Capsida's CEO Peter Anastasiou commented, "AbbVie has been an excellent partner, and we are excited to expand our collaboration into ophthalmology with the world leader in this therapeutic area." He added, "Combining AbbVie's expertise in eye disease drug development and commercialization with Capsida's fully integrated next-generation AAV engineering platform and manufacturing capabilities offers the potential to provide novel therapies enabling unprecedented benefit to patients with serious eye diseases."
(Source- PR Newswire)
About Capsida Biotherapeutics
Capsida Biotherapeutics Inc. is a leading gene therapy platform company that develops targeted, non-invasive gene therapies for patients suffering from severe and life-threatening genetic disorders. Its innovative approach allows for the treatment of rare and common diseases across all age groups. The company focuses on creating customized therapies that selectively target specific organ systems while minimizing exposure to non-targeted organs. Capsida is a fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, translational biology, advanced manufacturing capabilities, multi-modality cargo development and optimization, process development, as well as extensive clinical development expertise.
Read More